$Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open‐label, single‐arm, phase 1/2 study on 10 Japanese patients$

Rituximab therapy for refractory autoimmune bullous diseases: A multicenter, open‐label, single‐arm, phase 1/2 study on 10 Japanese patients

This was a multicenter study of rituximab, a chimeric monoclonal immunoglobulin G antibody directed against CD20, for the treatment of refractory autoimmune bullous diseases (pemphigus and pemphigoid). Ten patients (three with pemphigus vulgaris, six with pemphigus foliaceus and one with bullous pem...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of dermatology 2019-02, Vol.46 (2), p.124-130
Hauptverfasser:	Kurihara, Yuichi, Yamagami, Jun, Funakoshi, Takeru, Ishii, Maki, Miyamoto, Julia, Fujio, Yumi, Kakuta, Risa, Tanikawa, Akiko, Aoyama, Yumi, Iwatsuki, Keiji, Ishii, Norito, Hashimoto, Takashi, Nishie, Wataru, Shimizu, Hiroshi, Kouyama, Keisuke, Amagai, Masayuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Arthritis Autoantibodies Autoimmune diseases Bullous diseases Bullous pemphigoid CD19 antigen CD20 antigen CD20 antigens Corticosteroids Immunoglobulin G Immunotherapy Lymphocytes B Monoclonal antibodies Patients pemphigoid Pemphigus Peripheral blood Prednisolone Remission Rituximab Septic shock Skin diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!